Silexion Therapeutics Ltd.
SLXN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $188 | $294 | $4,404 | $4,345 |
| - Cash | $1 | $5 | $8 | $0 |
| + Debt | $4 | $0 | $0 | $0 |
| Enterprise Value | $191 | $290 | $4,396 | $4,345 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$16 | -$5 | -$4 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$16 | -$5 | -$3 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.64 | -4.42 | 0.035 | -0.046 |
| % Growth | 40.3% | -12,764.8% | 176.2% | – |
| Operating Cash Flow | -$8 | -$5 | -$3 | -$1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$8 | -$5 | -$3 | -$1 |